This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Endocrine/metabolic disease				
Gaucher's disease	Histone deacetylase (HDAC); glucocerebrosidase (GBA; GCase)	<p><i>In vitro</i> studies suggest HDAC inhibitors could help treat Gaucher's disease. In fibroblasts from patients with Gaucher's disease, the HDAC inhibitor Zolinza vorinostat increased levels of functional GCase enzyme compared with no treatment. Future studies could include testing HDAC inhibitors in animal models of the disease.</p> <p>Merck & Co. Inc. and Otsuka Pharmaceutical Co. Ltd. market Zolinza to treat cutaneous T cell lymphoma (CTCL). Istodax romidepsin, an HDAC inhibitor from Celgene Corp., is marketed to treat CTCL and lymphoma.</p> <p>SciBX 5(1); doi:10.1038/scibx.2012.17 Published online Jan. 5, 2012</p>	Patent and licensing status unavailable	<p>Lu, J. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Dec. 12, 2011; doi:10.1073/pnas.1119181109</p> <p>Contact: Zhengping Zhuang, National Institutes of Health, Bethesda, Md. e-mail: zhuangp@ninds.nih.gov</p> <p>Contact: Roscoe O. Brady, same affiliation as above e-mail: bradyr@ninds.nih.gov</p>